Stay updated on Bictegravir vs Dolutegravir in HIV/HepB Co-Infection Clinical Trial

Sign up to get notified when there's something new on the Bictegravir vs Dolutegravir in HIV/HepB Co-Infection Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Bictegravir vs Dolutegravir in HIV/HepB Co-Infection Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page displays the phase II pembrolizumab and cabozantinib study record, including its design, eligibility criteria, outcomes, locations, and documents, rather than a 403 error screen.
    Difference
    57%
    Check dated 2026-11-09T13:54:46.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0; the study record page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T16:12:20.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces a transition from using “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-26T14:36:23.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-19T14:55:55.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision label advances from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-12T15:17:48.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The study page now displays a 403 Forbidden message, blocking access to the study details and indicating that the page cannot be viewed at this time.
    Difference
    20%
    Check dated 2026-09-21T20:40:18.000Z thumbnail image

Stay in the know with updates to Bictegravir vs Dolutegravir in HIV/HepB Co-Infection Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Bictegravir vs Dolutegravir in HIV/HepB Co-Infection Clinical Trial page.